
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies Ltd has shown significant advancements in its strategic positioning within the regenerative medicine and aesthetics sectors, bolstered by a long-lasting patent expected to expire in 2039, which reinforces its competitive edge. The partnership with AbbVie has already yielded $24 million in milestone payments from a total potential of $50 million, reflecting strong market confidence in CollPlant’s rhCollagen technology. Additionally, the company's focus on cost optimization and preparations for human trials further amplifies its long-term growth potential and operational efficiency, enhancing its overall financial outlook.
Bears say
CollPlant Biotechnologies Ltd is experiencing challenges in generating consistent revenues, with dependence on its rhCollagen product sales and collaborations for financial stability. The company operates in multiple international markets, but its reliance on niche segments such as medical aesthetics and tissue engineering may hinder broad revenue growth. Additionally, while the proprietary technology presents a high barrier to entry for competitors, the market's overall uncertainties and CollPlant's financial performance metrics suggest potential headwinds that may affect future profitability.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares